Open Access Journal

ISSN : 2456-1304 (Online)

International Journal of Engineering Research in Electronics and Communication Engineering(IJERECE)

Monthly Journal for Electronics and Communication Engineering

Open Access Journal

International Journal of Science Engineering and Management (IJSEM)

Monthly Journal for Science Engineering and Management

ISSN : 2456-1304 (Online)

Development and validation of stability indicating method for estimation of Betrixaban in bulk and pharmaceutical formulation

Author : M. R. Ghante 1 S. Vaidya 2 [3] V. K. Bhusari 3

Date of Publication :20th May 2021

Abstract: Stability indicating reverse phase-high performance liquid chromatographic method is developed for the estimation of Betrixaban, an oral anticoagulant in formulation. HPLC separation was performed for the drug on the Hi-Q Sil C-18 column, 250 mm × 4.6 mm, 5.0 µ. A very simple mobile phase was used containing methanol: water (80: 20) v/v with a flow rate of 0.7 mL/min and analyte was examined at 272 nm by means of photodiode array (PDA) detector. Retention time of Betrixaban was found to be 2.91 min. For linearity study, the concentration range selected was 10-90 µg/mL and the calibration graph displayed a linear curve over the concentration vs area plot. The mean value of the correlation coefficient was 0.9998, slope was 8581.9 and intercept was 1989.1. The limit of detection (LOD) was 0.5980 µg/mL and limit of quantitation (LOQ) was 1.7381 µg/mL. RP-HPLC method was successfully applied to capsule formulation, no interference of drug and excipients was observed. The method was successfully validated as per ICH guideline in terms of precision, recovery and robustness. In stability studies, Betrixaban was exposed to various stressors; viz: acid, alkali, neutral, oxidation, photo degradation and dry heat. Betrixaban has shown more than 5 % degradation in alkaline, acidic, neutral and photo degradation studies; whereas it is showing less than 5 % degradation in oxidative and dry heat condition. The developed method being very simple and accurate can be applied for routine analysis of Betrixaban in pure and capsule formulation.

Reference :

    1. ICH, Stability Testing of New Drug Substances and Products, International Conference on Harmonization, Q1A (R2), IFPMA, Geneva, Switzerland 2003.
    2. PubChem. National Library of MedicineNational Center for Biotechnology Information. Compound summary for Betrixaban. (https://pubchem.ncbi.nlm.nih.gov/compound/B etrixaban#section=Computed-Descriptors)
    3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) July 2018. (https://www.ema.europa.eu/en/documents/asse ssment-report/dexxience-epar-refusal-publicassessment-report_.pdf
    4.  P. Harshalatha, B. C. Kothapalli and M. V. Chandrasekhar, “Stability indicating RP-HPLC method development and validation for the estimation of Betrixaban (BET) in bulk and its pharmaceutical formulations,” International Journal of Research in Pharmaceuticals Science, vol. 9, pp. 1572-1578, Oct 2018.
    5.  S. K. Mastannamma1, P. Navya, U. Annapurna and M. Varalaxmi, “Development and validation of a stability-indicating RP-HPLC method for the determination of Betrixaban in bulk and its laboratory synthetic mixer,” Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 1, pp. 71-79, Jan 2018.
    6.  T. Jasemizad and L. Padhye, “Simultaneous Analysis of Betrixaban and Hexazinone using Liquid Chromatography/Tandem Mass Spectrometry in Aqueous Solutions,” Method X, vol. 6, pp. 1863-1870, Aug 2019.
    7.  ICH, Q1A Stability Testing of New Drug Substances and Products, International Conference on Harmonization, Geneva October 1993.
    8. ICH, Q2A Validation of Analytical Procedure: Methodology International Conference on Harmonization, Geneva October 1994.
    9. ICH, Q2B Validation of Analytical Procedure: Methodology International Conference on Harmonization, Geneva March 1996.
    10.  ICH, Guidance on Analytical Method Validation, in: Proceedings of the International Convention on Quality for the Pharmaceutical Industry, Toronto, Canada, September 2002.

Recent Article